Abstract 1800P
Background
Dn-mCSPC is markedly aggressive, with shorter time to castration resistance and poorer overall survival than PLT-mCSPC (PMID: 28899723). We interrogate and validate differences in tumor gene expression profiles of dn-mCSPC vs. PLT-mCSPC.
Methods
In this IRB-approved retrospective study, eligibility criteria included histologically confirmed prostate adenocarcinoma (PC) and available RNA sequencing results from treatment naïve primary prostate tissue from a CLIA-certified lab [either Tempus (T) or Caris (C)]. T cohort was used for interrogation and C for validation. Pts in each cohort were categorized into two groups: dn-mCSPC vs. PLT-mCSPC. The DEseq2 pipeline was used to analyze differentially expressed genes between the groups. The data included the Log2 fold change, Wald-Test p-values, and Benjamini-Hochberg adjusted p-values for each differentially expressed gene. Results were subjected to Gene Set Enrichment Analysis (GSEA) to identify pathways enriched in each cohort. Bioinformatic analysis was performed using R v4.2.
Results
128 pts were eligible. T cohort: n=78 (dn-mCSPC=37, PLT-mCSPC=41); C cohort: n=50 (dn-mCSPC=30, PLT-mCSPC=20). Both T and C showed that dn-mCSPC had an increased expression of the TNFα signaling, hypoxia signaling, and inflammatory response pathway (PTW). PLT-mCSPC had higher expression of E2F target, G2M checkpoint, and MYC target PTW. Normalized enrichment scores (NES) are reported in the table.
Table: 1800P
Differential GSEA in dn-mCSPC vs. PLT-mCSPC (q value for each pathway <0.01)
T | C | ||
PTW | NES | PTW | NES |
TNFα signaling | 3.1 | TNFα signaling | 3.0 |
Hypoxia | 2.3 | Hypoxia | 2.3 |
Inflammatory response | 2.2 | Inflammatory response | 2.3 |
MYC target | -1.9 | MYC target | -1.5 |
G2M checkpoint | -2.0 | G2M checkpoint | -1.3 |
E2F target | -2.3 | E2F target | -1.5 |
Positive NES = upregulation in dn-mCSPC, negative NES = downregulation in dn-mCSPC
Conclusions
Pts with dn-mCSPC had PTW associated with tumor aggressiveness such as TNFα signaling, hypoxia, and inflammatory response. After external validation, these hypothesis-generating data may provide rationale for personalized therapy in men with PC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
B.L. Maughan: Financial Interests, Personal, Advisory Role: AbbVie, Pfizer, AVEO oncology, Janssen, Astellas, BMS, Clovis, Tempus, Merck, Exelixis, Bayer Oncology and Peloton Therapeutics; Financial Interests, Institutional, Funding: Exelixis (Inst), Bavarian-Nordic (Inst), Clovis (Inst), Genentech (Inst) and BMS (Inst). U. Swami: Financial Interests, Personal, Advisory Role: Seattle Genetics, Astellas Pharma, Exelixis, Imvax, and AstraZeneca; Financial Interests, Institutional, Funding: Janssen, Seattle Genetics/Astellas, and Exelixis. N. Agarwal: Financial Interests, Personal, Advisory Board, In the last two calendar years, I participated in the scientific advisory board of these pharma companies between February 2021 to April 2021. None after that: Merck, Aveo, Gilead, Lilly, Exelixis, Foundation Medicine; Financial Interests, Trial Chair, I am involved in the following phase 3 trials as the trial co-chair: TALAPRO-2, TALAPRO-3 (both Pfizer), and CONTACT-2 (Exelxis): Pfizer, Exelixis; Financial Interests, Institutional, Other, I serve in the leadership of my cancer center (Huntsman Cancer Institute, University of Utah. Salt Lake City, UT, USA). There are multiple research projects sponsored by these companies which pay money to my institution: Arnivas, Astellas, AstraZeneca, Bavarian Nordic, Bayer, BMS, Calithera, Celldex, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, GSK, Immunomedics, Janssen, Lava, Medivation, Merck, Nektar, Neoleukin, New Link Genetics, Novartis, Oric, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon.; Financial Interests, Steering Committee Member, I am involved in the steering committee of the trials sponsored by these pharmas with no personal honorarium: AstraZeneca, Calithera, Clovis, Crispr, Eisai, Eli Lilly, Exelixis, Immunomedics, Janssen; Financial Interests, Steering Committee Member, I am involved in the steering committee of the trials sponsored by these pharma companies with no personal honorarium: Merck, Nektar, New Link Genetics, Oric, Pfizer, Prometheus, Rexahn, Takeda, and Tracon. All other authors have declared no conflicts of interest.
Resources from the same session
1239P - NHS-Galleri trial enrolment approaches and participant sociodemographic diversity
Presenter: Charles Swanton
Session: Poster session 14
1241P - Decoding the glycan code: Pioneering early detection of non-small cell lung cancer through glycoproteomics
Presenter: Kai He
Session: Poster session 14
1242P - Implementing functional precision oncology in real-world patients: Translating extensive in vitro data into personalized treatment combining genetics and functional assays
Presenter: Dörthe Schaffrin-Nabe
Session: Poster session 14
1243P - Ocular surface squamous neoplasia early diagnosis using an AI-empowered autofluorescence multispectral imaging technique
Presenter: Abbas HABIBALAHI
Session: Poster session 14
1244P - AI-based accurate PD-L1 IHC assessment in non-small cell lung cancer across multiple sites and scanners
Presenter: Ramona Erber
Session: Poster session 14
1245P - A lymph nodal staging assessment model for various histologic types of small intestinal tumors
Presenter: YOUSHENG LI
Session: Poster session 14
1246P - Detection of alternative lengthening of telomeres (ALT) across cancer types based on tumor-normal multigene panel sequencing
Presenter: Juan Blanco Heredia
Session: Poster session 14
1247P - A detection model for EGFR mutations in lung adenocarcinoma patients based on volatile organic compounds
Presenter: Yunpeng Yang
Session: Poster session 14
1248P - Development of a high performance and noninvasive diagnostic model using blood cell-free microRNAs for multi-cancer early detection
Presenter: Jason Zhang
Session: Poster session 14
1249P - Whole genome sequencing-based cancer diagnostics in routine clinical practice: An interim analysis of two years of real-world data
Presenter: Jeffrey van Putten
Session: Poster session 14